InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (21 ops.)
Explore the complete record of transactions filed by French Glendon E. III, Board Member. Insider active across 1 companies, notably Pulmonx Corp. Aggregated, 32 reports have been recorded. Total volume traded: €6m. The latest transaction was disclosed on 1 June 2022 — Cession. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations32 total
€16,908998 shares@ €16.94170.032% mcap0.3% of flow
Common Stock
SEC:0001209191-22-034297:0·
025,000 shares0
Common Stock
SEC:0001209191-22-030215:0·
€26,1501,132 shares@ €23.10110.049% mcap0.4% of flow
Common Stock
SEC:0001209191-22-015792:0·
€299,11412,500 shares@ €23.92910.56% mcap4.9% of flow
Common Stock
SEC:0001209191-22-011844:0·
€286,29012,500 shares@ €22.90320.53% mcap9.9% of flow
Common Stock
SEC:0001209191-22-004643·
€286,29012,500 shares@ €22.90320.53% mcap4.7% of flow
Common Stock
SEC:0001209191-22-004643:0·
€501,00918,402 shares@ €27.22580.93% mcap17.2% of flow
Common Stock
SEC:0001209191-21-070463·
€501,00918,402 shares@ €27.22580.93% mcap8.1% of flow
Common Stock
SEC:0001209191-21-070463:0·
€45,94125,000 shares@ €1.83770.086% mcap1.6% of flow
Common Stock
SEC:0001209191-21-067978·
€41,0491,421 shares@ €28.88720.077% mcap1.4% of flow
Common Stock
SEC:0001209191-21-067999·
€17,99510,000 shares@ €1.79950.034% mcap0.6% of flow
Common Stock
SEC:0001209191-21-067997·
€45,94125,000 shares@ €1.83770.086% mcap0.7% of flow
Common Stock
SEC:0001209191-21-067978:0·
€41,0491,421 shares@ €28.88720.077% mcap0.7% of flow
Common Stock
SEC:0001209191-21-067999:0·
€17,99510,000 shares@ €1.79950.034% mcap0.3% of flow
Common Stock
SEC:0001209191-21-067997:0·
€362,43711,591 shares@ €31.26880.68% mcap12.5% of flow
Common Stock
SEC:0001209191-21-066199·
€362,43711,591 shares@ €31.26880.68% mcap5.9% of flow
Common Stock
SEC:0001209191-21-066199:0·
€559,02616,403 shares@ €34.08071.04% mcap19.2% of flow
Common Stock
SEC:0001209191-21-061431·
€559,02616,403 shares@ €34.08071.04% mcap9.1% of flow
Common Stock
SEC:0001209191-21-061431:0·
€825,58125,000 shares@ €33.02321.54% mcap28.4% of flow
Common Stock
SEC:0001209191-21-056974·
€825,58125,000 shares@ €33.02321.54% mcap13.4% of flow
Common Stock
SEC:0001209191-21-056974:0·
€48,1111,421 shares@ €33.85720.090% mcap1.7% of flow
Common Stock
SEC:0001209191-21-054857·
€48,1111,421 shares@ €33.85720.090% mcap0.8% of flow
Common Stock
SEC:0001209191-21-054857:0·
€31,3361,000 shares@ €31.33620.058% mcap1.1% of flow
Common Stock
SEC:0001209191-21-053007·
€31,3361,000 shares@ €31.33620.058% mcap0.5% of flow
Common Stock
SEC:0001209191-21-053007:0·
€8,1494,375 shares@ €1.86250.015% mcap0.3% of flow
Common Stock
SEC:0001209191-21-047261·
25 of 32 declarations
About French Glendon E. III
Glendon E. French III is an experienced medical-device executive best known for leadership roles in pulmonary care and respiratory technology. According to Pulmonx corporate filings, he has served on the company’s Board of Directors since December 2014 and returned as President and Chief Executive Officer in October 2025 after previously leading the company from December 2014 to March 2024. Between March and May 2024, he served as Senior Advisor before resuming the chief executive role. Pulmonx describes him as a seasoned healthcare leader with deep experience in medical devices and public-company governance. Before Pulmonx, Mr. French served as Chief Executive Officer and director of ApniCure from January 2014 to November 2014. He also held the position of President, Pulmonary Endoscopy at Boston Scientific from October 2010 to December 2012, giving him operating experience inside a major global medtech company. From December 2003 to October 2010, he was President, Chief Executive Officer, and a director of Asthmatx, a medical-device company focused on respiratory treatment. In addition, he served as Executive Chairman of Levita Magnetics International Corp. from August 2013 to January 2022 and has held board roles at Myka Labs, CoLabs, and EDAP TMS S.A. An executive biography cited in search results states that he co-founded, built, and sold three medical-device companies and took a fourth company public. That same source notes that during his long tenure leading Pulmonx, the company delivered more than 20% compound annual revenue growth and completed its 2020 IPO, raising $218.5 million. His career profile reflects a combination of operational leadership, commercialization expertise, strategic scaling, and board-level governance across the medtech sector.
